Dunhill Financial’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$53.1K Buy
233
+15
+7% +$3.47K 0.01% 323
2026
Q2
$46.3K Hold
218
– – 0.01% 345
2026
Q1
$42.8K Sell
218
-45
-17% -$8.74K 0.01% 335
2025
Q4
$45.6K Buy
263
+3
+1% +$546 0.01% 285
2025
Q3
$49.5K Buy
260
+2
+0.8% +$355 0.01% 260
2025
Q2
$46.5K Sell
258
-17
-6% -$2.95K 0.01% 248
2025
Q1
$46.6K Sell
275
-2
-0.7% -$329 0.02% 198
2024
Q4
$41.7K Sell
277
-113
-29% -$17.6K 0.02% 198
2024
Q3
$60.6K Buy
390
+13
+3% +$1.94K 0.03% 154
2024
Q2
$51.6K Buy
377
+125
+50% +$17.1K 0.03% 147
2024
Q1
$33.6K Buy
252
+2
+0.8% +$259 0.02% 139
2023
Q4
$34.4K Buy
+250
New +$32.9K 0.03% 122

Other funds holding DGX

Dunhill Financial's DGX Position: Q3 2026 in Review

Dunhill Financial increased its Quest Diagnostics (DGX) stake by 6.9% in Q3 2026, buying an estimated $3.47K and bringing the position to 233 shares worth $53.1K. The position accounts for 0.01% of the portfolio, ranked #323.

Dunhill Financial first reported a position in DGX in Q4 2023 and has held it in 12 quarters since. The position peaked at $60.6K in Q3 2024. 1,142 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

  • Dunhill Financial held 233 shares of Quest Diagnostics worth $53.1K as of Q3 2026.
  • Dunhill Financial bought 15 Quest Diagnostics shares in Q3 2026, an estimated $3.47K.
  • Quest Diagnostics made up 0.01% of Dunhill Financial's portfolio in Q3 2026, its #323 holding.
  • Dunhill Financial first reported a position in Quest Diagnostics in Q4 2023 and has held it in 12 quarters since.
  • Dunhill Financial's Quest Diagnostics position peaked at $60.6K in Q3 2024.
  • 1,142 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Dunhill Financial's 13F filing for Q3 2026, filed 16 Nov 2026.